⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
globenewswire.com
KYTX